These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 17173546)

  • 1. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
    Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
    Hideshima T; Podar K; Chauhan D; Ishitsuka K; Mitsiades C; Tai YT; Hamasaki M; Raje N; Hideshima H; Schreiner G; Nguyen AN; Navas T; Munshi NC; Richardson PG; Higgins LS; Anderson KC
    Oncogene; 2004 Nov; 23(54):8766-76. PubMed ID: 15480425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells.
    Adachi S; Yasuda I; Nakashima M; Yamauchi T; Yamauchi J; Natsume H; Moriwaki H; Kozawa O
    Oncol Rep; 2010 Jun; 23(6):1709-14. PubMed ID: 20428829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
    Ishitsuka K; Hideshima T; Neri P; Vallet S; Shiraishi N; Okawa Y; Shen Z; Raje N; Kiziltepe T; Ocio EM; Chauhan D; Tassone P; Munshi N; Campbell RM; Dios AD; Shih C; Starling JJ; Tamura K; Anderson KC
    Br J Haematol; 2008 May; 141(5):598-606. PubMed ID: 18397345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
    Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
    Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease.
    Armstrong J; Harbron C; Lea S; Booth G; Cadden P; Wreggett KA; Singh D
    J Pharmacol Exp Ther; 2011 Sep; 338(3):732-40. PubMed ID: 21610141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSP90 inhibitors strengthen extracellular ATP-stimulated synthesis of interleukin-6 in osteoblasts: Amplification of p38 MAP kinase.
    Hioki T; Tokuda H; Nakashima D; Fujita K; Kawabata T; Sakai G; Kim W; Tachi J; Tanabe K; Matsushima-Nishiwaki R; Otsuka T; Iida H; Kozawa O
    Cell Biochem Funct; 2021 Jan; 39(1):88-97. PubMed ID: 32567086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
    Mimura N; Fulciniti M; Gorgun G; Tai YT; Cirstea D; Santo L; Hu Y; Fabre C; Minami J; Ohguchi H; Kiziltepe T; Ikeda H; Kawano Y; French M; Blumenthal M; Tam V; Kertesz NL; Malyankar UM; Hokenson M; Pham T; Zeng Q; Patterson JB; Richardson PG; Munshi NC; Anderson KC
    Blood; 2012 Jun; 119(24):5772-81. PubMed ID: 22538852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
    Wen J; Feng Y; Huang W; Chen H; Liao B; Rice L; Preti HA; Kamble RT; Zu Y; Ballon DJ; Chang CC
    Leuk Res; 2010 Jan; 34(1):85-92. PubMed ID: 19608275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis.
    Poulaki V; Iliaki E; Mitsiades N; Mitsiades CS; Paulus YN; Bula DV; Gragoudas ES; Miller JW
    FASEB J; 2007 Jul; 21(9):2113-23. PubMed ID: 17400913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
    Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
    Combaret V; Boyault S; Iacono I; Brejon S; Rousseau R; Puisieux A
    Mol Cancer; 2008 Jun; 7():50. PubMed ID: 18534018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
    Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
    Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF-kappa B as a therapeutic target in multiple myeloma.
    Hideshima T; Chauhan D; Richardson P; Mitsiades C; Mitsiades N; Hayashi T; Munshi N; Dang L; Castro A; Palombella V; Adams J; Anderson KC
    J Biol Chem; 2002 May; 277(19):16639-47. PubMed ID: 11872748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells.
    Lea S; Li J; Plumb J; Gaffey K; Mason S; Gaskell R; Harbron C; Singh D
    J Mol Med (Berl); 2020 Mar; 98(3):361-374. PubMed ID: 31974640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor.
    Lea S; Harbron C; Khan N; Booth G; Armstrong J; Singh D
    Br J Clin Pharmacol; 2015 May; 79(5):756-66. PubMed ID: 25358442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
    Salem K; Brown CO; Schibler J; Goel A
    Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimyeloma activity of heat shock protein-90 inhibition.
    Mitsiades CS; Mitsiades NS; McMullan CJ; Poulaki V; Kung AL; Davies FE; Morgan G; Akiyama M; Shringarpure R; Munshi NC; Richardson PG; Hideshima T; Chauhan D; Gu X; Bailey C; Joseph M; Libermann TA; Rosen NS; Anderson KC
    Blood; 2006 Feb; 107(3):1092-100. PubMed ID: 16234364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.